(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/096242 A1

(51) International Patent Classification[7]: A61K 31/716, 35/78, A61P 17/00

(21) International Application Number: PCT/CA2004/000662

(22) International Filing Date: 30 April 2004 (30.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/467,146 2 May 2003 (02.05.2003) US
60/477,048 10 June 2003 (10.06.2003) US

(71) Applicant (*for all designated States except US*): CEAPRO INC. [CA/CA]; 4046 EDC, University of Alberta, 8303-114 Street, Edmonton, Alberta T6G 2E1 (CA).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): REDMOND, Mark, J. [CA/CA]; 1160492 Avenue, Edmonton, Alberta T6C 1B3 (CA). FIELDER, David, A. [CA/CA]; 9911-68 Street, Edmonton, Alberta T6A 2S6 (CA).

(74) Agents: ERRATT, Judy, A. et al.; Gowling Lafleur Henderson LLP, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P 1C3 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING CEREAL BETA (1-3) BETA (1-4) GLUCAN

(57) Abstract: The present invention relates to pharmaceutical compositions comprising a β (1-3) β (1-4) glucan and a pharmaceutically active agent or a botanical extract. A method to extract and purify cereal β-glucan is also described. The high purity of the cereal β-glucan obtained according to the present invention allows for the preparation of clear, colourless viscous liquid preparations. These liquid preparations are stable to gelling effects when kept at ambient temperatures and low ash concentrations, and can be used to prepare the pharmaceutical compositions of the present invention.

WO 2004/096242 A1

PHARMACEUTICAL COMPOSITIONS COMPRISING CEREAL BETA(1-3) BETA(1-4) GLUCAN

TECHNICAL FIELD

The present invention relates generally to cereal β-glucans. More particularly, the invention relates to pharmaceutical compositions comprising a β (1-3) β (1-4) glucan and a botanical extract, or a pharmaceutically active agent.

BACKGROUND OF THE INVENTION

Gums are either hydrophobic or hydrophilic substances of molecular weight ranging from 10,000 to 50,000,000 Daltons, which in an appropriate solvent produce gels or highly viscous suspensions or solutions at low dry substance content. Gums commonly used in food, medicine, and industrial products include starches, cellulose derivatives, pullulan, agar, aloe, gellan, guar gum, locust bean gum, pectin, algin, carrageenan, xanthan, β-glucan, and gum arabic (see Whistler, R.L. (1993) *Industrial Gums: Polysaccharides and their derivatives* Eds. Whistler R.L. and BeMiller J.N. (Academic Press) p 2).

Glucans are homopolysaccharides consisting only of glucose. However, since it is possible to link the glucose molecules in different stereochemical configurations, glucans are a diverse group of compounds with differing chemical, physical, and functional properties.

Chemical structures of polysaccharides are of prime importance in determining their properties. This can be appreciated by comparing the properties of some common homoglucans. For example, cellulose, a β (1-4)-D-glucan, is water insoluble and highly crystalline compared to other polysaccharides. Amylose, an α (1-4)-D-glucan, is sparingly soluble in water, crystallizes less well than cellulose, and can form rigid thermo-reversible gels. Dextran, a (1-6)-α-glucan, with a small degree of branching, is extremely water soluble and non-gel forming. (See Dea, I.C.M. in (1993) *Industrial Gums: Polysaccharides and their derivatives* Eds. Whistler R.L.

and BeMiller J.N. (Academic Press) p 21).

Oat β (1-3) β (1-4) glucan is classified as a viscous gum, (see Wood, P.J. (1993) *Oat Bran* Ed P.J. Wood (American Association of Cereal Chemists, Inc. St. Paul, MN)). Cereal β (1-3) β (1-4)-glucans are structural polysaccharides present in the cell walls of cereals, such as barley and oat, among others.

Oat β (1-3) β (1-4) glucan is recognised by the U.S. FDA as an agent that may aid in the prevention of heart disease. In 1997, the FDA allowed oat products to make a health claim. It is important to note that no other β-glucan source, yeast, fungal, bacterial, or cereal is recognised as having these effects. Oat β (1-3) β (1-4)-glucans are therefore distinct.

Unmodified oat β (1-3) β (1-4) glucan forms highly viscous solutions in water at concentrations >0.75%. At concentrations >1.2% the solutions have the consistency of a thick hydrogel.

Glucans of significantly different molecular structure and with different physical and chemical properties compared to oat are found in yeast, fungi, and certain bacteria and genetically engineered bacteria. For example, gellan, polymeric (1-3) β-D-glucopyranosyl [β (1-3)-glucan] produced in *Alcaligenes faecalis* is found in Curdlan (Takeda Chemical Ind. Ltd.), β (1-3) α (1-6) glucopyranoside produced in *Aureobasidium pullulans* is found in pullulan, and β (1-3) β (1-6) glucopyranoside is found in yeast.

The molecular weight of the glucans varies with source. Table 1 shows the average molecular weight of typical gums.

Table 1: Typical Molecular Weight Range of Common Gums

GUM	AVERAGE MOLECULAR WEIGHT
Oat β (1-3) β (1-4) glucan	500,000 - 1,000,000
Pullulan	50,000 - 100,000
Curdlan	~500,000
Methyl cellulose	10,000 - 200,000
Carrageenan	4,500,000
Xanthan	15,000,000 - 50,000,000
Sodium alginate	10,000 - 18,000,000

The viscosity of a 1% solution of different polysaccharide gum solutions varies with origin and chemical nature. Table 2 shows the viscosity of 1% solutions of typical gums.

TABLE 2: Typical Viscosity Ranges of 1% Solutions of Common Gums, Measured at 25°C

GUMS	1% SOLUTION VISCOSITY, cP
Oat β (1-3) β (1-4) glucan	500-1500
Pullulan	2
Gum Arabic	1-5
Methyl cellulose	200
Tamarind gum	100-200
Guar gum	2,000-3,000
Locust bean gum	2,000-3,000
Xanthan	2,000-3,000
Sodium alginate	200-700

The solubility properties of glucans differ according to their source. For example, cereal β (1-3) β (1-4) glucans are normally soluble in aqueous solvents, whereas yeast *(Saccharomyces cerevisiae)* β (1-3) β (1-6)-*glucans* are insoluble in aqueous solvents. Soluble-glucans are desirable. Yeast β-glucan has been solubilized by the addition of phosphate groups (see Williams *et al. Immunopharmacol.* 22: 139-156 (1991). Jamas *et al.* (U.S. Patent No. 5,622,939) describes methods to extract soluble β (1-3) β (1-6) glucan from *Saccharomyces cerevisiae*. The method described is complex involving acid hydrolysis, base hydrolysis and the extensive use

of centrifugation and ultrafiltration. No details are provided as to the stability of the solubilized yeast β (1-3) β (1-6) glucan.

A number of prior art references disclose methods of preparing-glucans and liquid-glucan compositions from cereals. Among these prior art references are the following:

Beer, *et al.*, Extraction of Oat Gum from Oat Bran: Effects of Process on Yield, Molecular Weight Distribution, Viscosity and (1-3) (1-4) beta-D-Glucan Content of the Gum, Cereal Chemistry 73(1): 58-62 (1996). This reference describes the use of alcohols in an amount equal to or greater than 50% (v/v) to achieve precipitation. The purity of the recovered glucans was reported to be between 22 and 63%.

Wood *et al.*, Large Scale Preparation and Properties of Oat Fractions Enriched in (1-3)(1-4) beta-D-Glucan, Cereal Chemistry 66(2): 97-103 (1989). This reference describes the use of alcohols in an amount equal to or greater than 50% (v/v) to achieve precipitation of glucans.

U.S. Patent No. 6,323,338 discloses a method of isolating oat β-glucan as an enriched skin from an extract of oat bran. The disclosed method does not utilize low concentrations of short-chain alcohols for the precipitation of the glucan.

Redmond (U.S. Patent No. 6,284,886) discloses compositions of cereal β (1-3) β (1-4) glucans, and methods of producing these compositions. The disclosed compositions meet the strict requirements of the cosmetics industry, in terms of their viscosity, shear strength, and moisture-enhancing properties. No method for the extraction or purification of β (1-3) β (1-4) glucan is described.

SUMMARY OF THE INVENTION

The present invention relates generally to cereal β-glucans. More particularly, the invention relates to pharmaceutical compositions comprising a β (1-3) β (1-4) glucan and a botanical extract, or a pharmaceutically active agent.

In a first aspect, the present invention provides a pharmaceutical composition comprising:

an effective amount of a β (1-3) β (1-4) glucan, and

an effective amount of a botanical extract, or a pharmaceutically active agent.

In one example, the composition of the first aspect of the present invention comprises:

an effective amount of a β (1-3) β (1-4) glucan, and

an effective amount of a botanical extract, wherein the botanical extract is an extract of Guarana, *Ginkgo biloba*, Kola nut, Goldenseal, Golo Kola, *Schizandra*, Elderberry, St. John's Wort, Valerian and *Ephedra*, black tea, white tea, java tea, garlic oil, fiber, green tea, lemon oil, mace, licorice, onion oil, orange oil, rosemary, milk thistle, *Echinacea*, Siberian ginseng or *Panax ginseng*, lemon balm, *Kava kava*, matte, bilberry, soy, grapefruit, seaweed, hawthorn, lime blossom, sage, clove, basil, curcumin, taurine, wild oat herb, oat grain, dandelion, gentian, aloe vera, hops, cinnamon, peppermint, grape, chamomile, fennel, marshmallow, ginger, slippery elm, cardamon, coriander, anise, thyme, rehmannia, eucalyptus, menthol, schisandra, withania, cowslip, lycium, or passion flower, or

an effective amount of a pharmaceutically active agent selected from the group consisting of beta-sitosterol, caffeine, cafestol, D-limonene, kabweol, nomilin, oltipraz, sulphoraphane, tangeretin, folic acid, and menthol.

In another example of the composition of the first aspect of the present invention, the botanical extract is an extract of oat grain, which preferably comprises avenanthramide.

In another example, the composition of the first aspect of the present

invention comprises:

an effective amount of a β (1-3) β (1-4) glucan, and

an effective amount of a pharmaceutically active agent selected from the group consisting of an antihistamine, a decongestant, a corticosteroid, a non-steroidal anti-inflammatory drug, a bronchodilator, a vasodilator, such as nitroglycerin, or a local anaesthetic.

The β (1-3) β (1-4) glucan of the above-defined pharmaceutical compositions may be derived from a cereal grain or a part of the cereal grain. In an example, the cereal is selected from the group consisting of a cultivar of barley, a cultivar of oat, a cultivar of wheat, a cultivar of rye, a cultivar of sorghum, a cultivar of millet, a cultivar of corn, and a mixture thereof.

The β (1-3) β (1-4) glucan used in the pharmaceutical compositions of the present invention may be a β (1-3) β (1-4) glucan composition having a purity of at least about 75%, and containing less than10% ash impurities, less than 10% protein impurities, and less than 5% lipid impurities. More particularly, the present invention relates to a pharmaceutical composition comprising a β (1-3) β (1-4) glucan composition having a purity of at least about 92%, and containing less than 3.5% ash impurities, less than 3.5 % protein impurities, and less than 1% lipid impurities. The cereal β-glucan composition can also have a clarity value of from about 5 to about 100 NTU.

In another example, the β (1-3) β (1-4) glucan used in the pharmaceutical compositions of the present invention may be formed by a method of isolating a β (1-3) β (1-4) glucan from a milled cereal grain or a milled part of the cereal grain, comprising:

(i) extracting the milled cereal grain or the milled part of the cereal grain with an alkaline solution to produce an extract containing at least about 0.4 weight percent β (1-3) β (1-4) glucan;

(ii) removing insoluble material, and removing particulate material having a particle size of greater than about 0.2 μm from the extract to produce a purified extract;

(iii) adding from about 10% to about 25% (w/w) of a C_1-C_4 alcohol to the purified extract to precipitate the β (1-3) β (1-4) glucan, and

(iv) isolating the β(1-3) β(1-4) glucan.

In an example of the above-defined method, about 10% to about 20% (w/w) of an alcohol selected from the group consisting of methanol, ethanol and isopropanol is used to precipitate the β (1-3) β (1-4) glucan from the filtrate. Preferably, about 10% to about 20% (w/w) of ethanol is used to precipitate the β (1-3) β (1-4) glucan.

In an example of the methods described above, the step of removing particulate material comprises:

one, or more than one step of adding a flocculant, a coagulant or both a flocculant and a coagulant to the extract to coagulate particulate material having a particle size of greater than about 0.2 μm, and removing coagulated material from the extract;

digesting starch material in the extract, and

filtering out particulate material having a particle size of greater than about 0.2 μm from the extract to produce a purified extract.

In an example of the just described method, the starch material is digested with an enzyme, such as an amylase. More particularly, the enzyme is digested with an amylase that does not require a calcium cofactor. In another example, the alkaline extract is neutralized before the starch material is digested. In a further example, the enzyme is inactivated following the digestion of the starch material, by, for example, acidifying the alkaline extract containing the digested starch material.

The cereal used in the methods described above may be selected from the group consisting of a cultivar of barley, a cultivar of oat, a cultivar of wheat, a cultivar of rye, a cultivar of sorghum, a cultivar of millet, a cultivar of corn, and a mixture thereof.

In another example, the cereal grain or the part of the cereal grain extracted in step (i) is in the form of a coarsely-milled flour or a finely-milled flour.

In other examples of the above-described methods, the pH value of the alkaline solution is from about 9.00 to about 10.00, from about 9.25 to about 9.75, or from about 9.30 to about 9.50. In another example, the step of extracting (step i) is carried out over a period of about 15 to about 45 minutes.

In a further example of the above-defined methods, the precipitation step is conducted at a temperature of from about 1°C to about 10°C, or from about 1°C to about 5°C. In an even further example, the alcohol used to conduct the precipitation step is cooled to a temperature of at least about -20°C before being added to the β(1-3) β(1-4) glucan solution.

The methods defined above may further comprise one, or more than one step of dissolving the isolated β (1-3) β (1-4) glucan from step (iv) in an aqueous solution, precipitating the β (1-3) β (1-4) glucan by adding about 10% to about 25% (w/w) of the C_1-C_4 alcohol to the aqueous solution, and isolating the β (1-3) β (1-4) glucan.

In a further example, the β (1-3) β (1-4) glucan used in the pharmaceutical compositions of the present invention may be formed by a method of isolating a β (1-3) β (1-4) glucan from a milled cereal grain or a milled part of the cereal grain, comprising:

(i) extracting the milled cereal grain or the milled part of the cereal grain with an alkaline solution to produce an extract comprising at least about 0.4 weight percent β (1-3) β (1-4) glucan;

(ii) removing insoluble material, and removing particulate material having a particle size of greater than about 0.2 μm from the extract to produce a purified extract, wherein the step of removing particulate material comprises:

one, or more than one step of adding a flocculant, a coagulant or both a flocculant and a coagulant to the extract to coagulate particulate material having a particle size of greater than about 0.2 μm, and removing coagulated material from the extract;

enzymatically digesting starch material in the extract, and

filtering out particulate material having a particle size of greater than about 0.2 μm from the extract to produce the purified extract;

(iii) adding about 10% to about 25% (w/w) of a C_1-C_4 alcohol to the purified extract to precipitate the β(1-3) β(1-4) glucan, and

(iv) isolating the β(1-3) β(1-4) glucan.

The purification method of the present invention differs from the method disclosed in U.S. Patent No. 6,323,338 in that fine particulate matter is removed, as well as a large proportion of protein (~90%) present in the original cereal grain.

The purification method of the present invention allows the use of concentrations of alcohol of less than 50% (w/w), for example, 10-25% aqueous alcoholic solutions to precipitate cereal β-glucan. The capability of using such concentrations of alcohol is surprising in view of prior art purification procedures, which have used 50% ethanol solutions to precipitate cereal β-glucan (see, for example, Wood *et al.* Large Scale Preparation and Properties of Oat Fractions Enriched in β (1-3) β (1-4) D-glucan Cereal Chem. 66 97-103 (1989)). It is believed

that the removal of the particulate matter and most of the protein material, according to the method of the present invention, reduces the amount of alcohol needed to precipitate the cereal β-glucan from solution.

The use of 10-25% aqueous alcoholic solutions to precipitate the cereal β-glucan is advantageous in that severe dehydration of the cereal β-glucan is avoided, resulting in a cereal β-glucan precipitate that can be easily suspended in water. Furthermore, the use of these relatively lower alcohol concentrations allows the starting cereal grain to be processed in a standard manufacturing plant without the need for explosion proof environmental systems. For example, use of 20% aqueous alcoholic solutions at a final temperature of 7-10°C produces a vapor pressure lower than the Lower Explosion Limit (LEL) of ethanol. Furthermore, the efficiency of the extraction step and the production of intermediate solutions containing cereal β-glucan at a concentration of greater than 0.4% permits processing using relatively small process volumes.

DESCRIPTION OF PREFERRED EMBODIMENT

The present invention relates generally to cereal β-glucans. More particularly, the invention relates to pharmaceutical compositions comprising a β (1-3) β (1-4) glucan and a botanical extract, or a pharmaceutically active agent.

The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, cereal chemistry, and biochemistry, within the skill of the art. Such techniques are explained fully in the literature. See for example, *Industrial Gums: Polysaccharides and their derivatives* Eds. Whistler R.L. and BeMiller J.N. (Academic Press), *Oats: Chemistry and Technology* ed. Webster F.H. (American Association of Cereal Chemists, St. Paul, MN).

All publications, patents, and patent applications cited herein, whether *supra* or *infra*, are incorporated by reference in their entirety.

As used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural references unless the content clearly indicates otherwise.

Definitions

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

By "cereal" is meant any of several grains such as, but not limited to, cultivars of barley, oat, wheat, rye, sorghum, millet, and corn.

By "glycan" is meant a polymer of monosaccharides linked together by glycosidic bonds.

By "glucan" is meant a homopolysaccharide consisting only of glucose.

By "cereal β-glucan" is meant a glucan with a β (1-3)-linked glucopyranosyl backbone, or a β (1-4)-linked glucopyranosyl backbone, or a mixed β (1-3) β (1-4)-linked glucopyranosyl backbone, which is derived from a cereal source.

By "β (1-3) β (1-4) glucan" is meant a cereal β-glucan.

By "gum" is meant a plant or microbial polysaccharide or their derivatives, which are dispersible in either cold or hot water to produce viscous mixtures or solutions. Gums may be classified by origin, and include: exudate gums, seaweed gums, seed gums, starch and cellulose derivatives, and microbial gums.

By "compound of interest" is meant any pharmaceutical, medicinal, botanical or therapetic material mixed with a β (1-3) β (1-4) glucan to produce a composition.

By "flocculant" and "coagulant" are meant molecules that can coalesce with suspended solids (fines) to form larger denser particles that can be separated by centrifugation. In particular examples, coagulants are molecules that can bring together suspended particles that are less than 1 μm in size, and flocculants are molecules that can bring together suspended particles that are greater than 1 μm in size.

By "insoluble material" is meant material that is not soluble under the initial alkaline extraction conditions of the method of the invention. Non-limiting examples of such material include fibre, hemicellulose and lignins.

By "particulate material" is meant a solid or colloidal material having a particle size of greater than about 0.2 μm.

By "a milled cereal grain" or "a milled part of the cereal grain" is meant a cereal grain or part of the cereal grain, which has been ground, abraded or chopped into a meal or flour. In a particular example, the milled part of the cereal grain is bran that has been abraded from the cereal grain, and optionally further ground and

purified by, for example, air classification or sieving to provide a specific particle profile.

By "effective amount" is meant the amount of the one, or more than one compound of interest necessary to achieve a desired effect, such as a physiological effect, or a stimulatory effect.

By "sequestered" is meant the incorporation, entrapment, or solubilization of hydrophilic compounds, or hydrophobic compounds, for example, small molecular weight hydrophobic compounds, such as essential oils, pharmaceutical, medicinal, and therapeutic agents.

The compositions of the present invention can be formed by mixing an aqueous solution comprising about 0.01 wt. % to about 20 wt. %, about 0.01 wt. % to about 1.2% wt. %, about 0.1 wt. % to about 1.1 wt. %, or about 0.5 wt. % to about 1 wt. % of the β (1-3) β (1-4) glucan with one, or more than one compound of interest, such as a botanical extract, or a pharmaceutically active agent. The one, or more than one compound of interest may be present in an amount of from about 0.01 wt. % to about 40 wt. %, from about 0.01 wt. % to about 25 wt. %, from about 0.01 wt% to about 4 wt. %, from about 0.1 wt. % to about 1.4 wt. %, or from about 0.5 wt. % to about 1.2 wt. %. It is preferred that the resulting compositions be left undisturbed after being mixed for a period of time sufficient to allow the formation of a homogeneous composition in the form of a suspension, emulsion or gel. In many cases, the amount of time required to obtain a homogeneous composition is from about eight to about 16 hours.

It is to be appreciated, however, that shorter or longer periods of time may be required, depending on the quantity and purity of the β (1-3) β (1-4) glucan used, as well as on the quantity and nature of each of the one, or more than one compound of interest. Compositions of the present invention, which are in the form of a gel may be converted into a more fluid state by gentle agitation.

Without wishing to be bound by theory, the formation of the homogeneous suspension, emulsion or gel is believed to be caused by the one, or more than one

compound of interest being sequestered or encapsulated within the β (1-3) β (1-4) glucan, and by the subsequent formation of hydrogen bonds between molecules of the one, or more than one compound of interest and the β (1-3) β (1-4) glucan. Another possibility is that the β (1-3) β (1-4) glucan acts as a surfactact or emulsifying agent by reducing the interfacial tension at the boundaries between the one, or more than one compound of interest and the aqueous phase within which the β (1-3) β (1-4) glucan is dispersed, and, consequently, effectively solubilizes the one, or more than one compound within the aqueous phase.

Examples of the botanical extract that may be used in the pharmaceutical compositions according to the present invention include, without limitation, extracts of Guarana, *Ginkgo biloba*, Kola nut, Goldenseal, Golo Kola, *Schizandra*, Elderberry, St. John's Wort, Valerian and *Ephedra*, black tea, white tea, java tea, garlic oil, fiber, green tea, lemon oil, mace, licorice, onion oil, orange oil, rosemary, milk thistle, *Echinacea*, Siberian ginseng or *Panax ginseng*, lemon balm, *Kava kava*, matte, bilberry, soy, grapefruit, seaweed, hawthorn, lime blossom, sage, clove, basil, curcumin, taurine, wild oat herb, oat grain, dandelion, gentian, aloe vera, hops, cinnamon, peppermint, grape, chamomile, fennel, marshmallow, ginger, slippery elm, cardamon, coriander, anise, thyme, rehmannia, eucalyptus, menthol, schisandra, withania, cowslip, lycium, and passion flower.

In a particular example, the botanical extract is an extract of an oat grain. More particularly, the botanical extract is an oat grain extract, which contains avenanthramide.

As an example of a pharmaceutically active agent there is mentioned an antihistamine, a decongestant, a corticosteroid, a non-steroidal anti-inflammatory drug, a bronchodilator, a vasodilator, or a local anaesthetic.

Other examples of the pharmaceutically active agent botanical extract that may be used in the pharmaceutical compositions of the present invention include, without limitation, beta-sitosterol, caffeine, cafestol, D-limonene, kabweol, nomilin, oltipraz, sulphoraphane, tangeretin, folic acid, and menthol.

Cereal beta glucans suitable for use in making the compositions of the present invention are available in powdered form from several commercial suppliers, such as Sigma Chemical Co. (St. Louis, MO) and Ceapro Inc. (Edmonton, AB, Canada). Solutions of beta glucan can be prepared in the manner described in U.S. Patent No. 6,284,886.

The beta glucan solutions used in preparing the compositions of the present invention may also be prepared from a beta glucan composition having a purity of from about 65% to about 100%, from about 75% to about 100%, or from about 85% to about 100%. In particular, beta glucan solutions used in preparing the compositions of the present invention generally contain less than 20%, more particularly less than 15%, even more particularly less than 10%, most particularly less than 5% of impurities, such as protein, lipid, carbohydrate, and particulate impurities.

In another example, the β (1-3) β (1-4) glucan used in the pharmaceutical compositions of the present invention may be formed by a method of isolating a β (1-3) β (1-4) glucan from a milled cereal grain or a milled part of the cereal grain, comprising:

(i) extracting the milled cereal grain or the milled part of the cereal grain with an alkaline solution to produce an extract containing at least about 0.4 weight percent β (1-3) β (1-4) glucan;

(ii) removing insoluble material, and removing particulate material having a particle size of greater than about 0.2 μm from the extract to produce a purified extract;

(iii) adding from about 10% to about 25% (w/w) of a C_1-C_4 alcohol to the purified extract to precipitate the β (1-3) β (1-4) glucan, and

(iv) isolating the β(1-3) β(1-4) glucan.

Cereal β-glucan can be isolated according to the purification method of the present invention from a milled whole cereal grain or a milled part of the cereal grain, such as the milled bran of the cereal grain. Preferably, the bran of the cereal grain is used. The cereal grain, or a part thereof that is extracted may be in the form of a coarsely milled meal or finely milled flour. The cereals that can be used in the present invention include, without limitation, any one of the cultivars of barley, oat, wheat, rye, corn, sorghum, and millet.

In the first step of the purification method of the present invention, the milled grain or the milled part of the grain is slurried with reverse osmosis (RO) purified or deionized (DI) water to a final solids concentration of about 4 to about 10%, or about 6 to about 8%.

The pH value of the water used in the first step of the purification method can be from about 9.00 to about 10.00, more particularly, from about 9.25 to about 9.75, or from about 9.30 to about 9.50, and can be adjusted using an inorganic base, such as sodium hydroxide or potassium hydroxide. In one example, potassium hydroxide is used at a concentration from about 28 mM to about 35 mM. The use of a solution having a value of pH of between 9-10 generally reduces the amount of non-glucan polysaccharides and protein that is extracted during the first step, and, therefore, provides selective extraction of high molecule weight cereal β glucan molecules.

The extraction of the cereal β-glucan can be carried out over a 15 to 45 minute period, or over a 15-30 minute period. It is to be appreciated, however, that longer or shorter periods of extraction may be used depending on the type of cereal β-glucan used.

In the second step of the purification process, any insoluble material that cannot be extracted, for example hemicelluloses or lignins, is removed. Examples of methods that can be used to separate the insoluble material include, without limitation, centrifugation, preferably with a decanter centrifuge, and vibrating screening.

Any fine particulate material including some protein-based material is also removed from the alkaline solution in the second step of the method of the present invention. This material can be removed by adding an external flocculant or coagulant, or both. The flocculants or coagulants that can be used in the second step can have either a net positive, negative, or neutral charge. The coagulation step may be repeated one, or more than one time.

Examples of flocculants that can be used include, without limitation synthetic flocculants, such as polyacrylamides, quaternary acrylate salts and natural flocculant macromolecules such as chitosan, a natural polymer derived from chitin. Particular examples of flocculants include Tramfloc® (Tramfloc Inc.), the cationic flocculant SURFLOC® 34030 (Jes-Chem Ltd.), polyacrylamide (PAM) flocculants such as an Aquamark® AQ 600 Series flocculant, or a SuperFloc® C-500 Series flocculant (QEMI Inc.).

Examples of coagulants that can be used in the method of the present invention include, without limitation, inorganic electrolytes, such as alum, lime, ferric chloride, and ferrous sulfate, organic polymers, synthetic polyelectrolytes with anionic or cationic functional groups, and polyacrylamides.

The flocculants, coagulants, or a mixture thereof, may be used at a concentration of from about 0.09% to about 0.20% (w/vol), or from about 0.10% to about 0.13% (w/vol).

The alkaline solution may be incubated with the flocculant or coagulant for about 10 to about 40 minutes, or from about 10 to about 20 minutes at a temperature of from about 20 to about 40°C, or from about 20 to about 30°C. It is to be appreciated, however, that longer or shorter periods of time can be used to effect coagulation of the particulate material.

If negatively charged materials are to be removed from the solution containing the cereal β-glucan, then it is preferred that the flocculant or coagulant be positively

charged. If positively charged materials are to be removed from the solution, then a negatively-charged flocculant or coagulant is preferred.

Without wishing to be bound by theory, the flocculants and coagulants that can be used in the method of the present invention function by forming large, dense aggregates with fine particulate matter, which can be easily separated from the aqueous solution containing the cereal β-glucan.

The coagulated material may be removed by centrifugation, using, for example, a disk-stack centrifuge. Other physical separation methods known to those of skill in the art can also be used to effect the separation of the coagulated material.

In the second step, any starch or related material that is present may be digested using an enzyme, such as, but not limited to an amylase. The enzyme may be used at a concentration of from about 0.05% to about 0.20% (vol/vol), from about 0.09% to about 0.15% (vol/vol), or from about 0.09% to about 0.11% (vol/vol). If an amylase is used, it is preferred that the alkaline solution be brought to an approximately neutral value of pH (i.e. ~pH 7) before adding the amylase. In an example, the solution containing the amylase is heated to a temperature of from about 50°C to about 100°C, or from about 70°C to about 90°C for about 20 to about 30 minutes to gelatinize the starch. The amylase will hydrolyse the starch and any related material. Generally, the amylase that is chosen to break down the starch material should be functional and stable within the temperature ranges indicated above. It is particularly preferred that the amylase not require a calcium co-factor to digest the starch material. Examples of such an amylase, include, without limitation, Termamyl® LC (Novozymes A/S), and Spezyme® FRED (Genencor International Inc.).

The completion of the hydrolysis reaction is determined when a sample withdrawn from the solution no longer produces a positive iodine test. At this point, the enzyme may be inactivated, by, for example, reducing the pH to a value of about 3.5 to about 4.0. The pH of the solution can be reduced using strong inorganic acids, such as hydrochloric acid or weak organic acids, such as malic acid or citric acid. It is

preferred, however, that a strong inorganic acid, such as hydrochloric acid be used. In addition, it is preferred that the temperature of the solution be raised to between 85-90°C to denature protein present in solution.

The resulting acidified solution can then be filtered to remove any particulates and microbiological contaminants, through a filter pad that preferably has a cutoff point of about 20 μm. This filter may be coated with a pre-coat of a filter aid having a thickness of about 2 to about 5 mm, such as Celite® C65 (World Minerals), which has a nominal porosity of about 0.2 μm. An equivalent weight of a filter-aid, for example, an acid-washed pharmaceutical grade filter-aid, such as Celite® C300 (World Minerals), may also be added as a body feed to the acidified solution prior to conducting the filtration step.

The filtration can be conducted using any one of a number of filtration devices. One particular example of a filtration device that can be used is a filter-press. In the case where the particle size of the material contained in the extract is less than 0.5 microns, then ceramic microfiltration and ultrafiltration can alternatively be used to filter the acidified solution.

In the third step of the purification method, the cereal β-glucan is precipitated from solution by adding a C_1-C_4 alcohol. The alcohol used to precipitate out the cereal β-glucan may be selected from the group consisting of methanol, ethanol, and isopropanol. If the cereal β-glucan isolated according to the procedure of the present invention is to be used in the preparation of a pharmaceutical, or an edible product, then it is preferred that ethanol or isopropanol, more preferably, ethanol, be used.

As the concentration of the alcohol in the solution is increased, the cereal β-glucan is precipitated out as a fine colloidal suspension. The total amount of alcohol that is required to carry out the precipitation step may depend on the concentration of cereal β-glucan in solution. The alcohol is added to a final concentration of about 10% to about 25% by volume, preferably from about 15% to about 17% by volume. The present invention, therefore, avoids the use of high concentrations of alcohol (i.e. concentrations of greater than 50% by volume), which can cause severe dehydration

of the cereal β-glucan and result in the need for homogenizers to disperse the cereal β-glucan.

It is preferred that the precipitation step be conducted at a low temperature, such as from about 1°C to about 10°C, preferably from about 1°C to about 5°C. In addition, it is preferred that the alcohol used in the precipitation step be cooled to a temperature of at least about -20°C before adding it to the β(1-3) β(1-4) glucan solution.

The final isolated cereal β-glucan material is a microdispersion or a nanodispersion, which is free of large particulates, and does not require additional filtration. Aqueous solutions of the cereal β-glucan isolated according to the present invention remain homogeneous after more than a year of being prepared.

Centrifugation using, for example, a disk-stack centrifuge, or a hydrocyclone can be used to isolate the suspended cereal β-glucan. If desired, the isolated β-glucan can be re-dissolved in an aqueous solution and re-precipitated with the C_1-C_4 alcohol to increase the purity of the β-glucan. The isolated solid can then be dried to a powder using, for example, vacuum drying, spray drying or drum drying. The preferred method of drying is vacuum drying, which produces a coarsely granular solid that can be further milled to a desired particle size, for example by hammer, pin or jet-milling. Vacuum drying, however, requires less heat, and can produce a relatively purer cereal β-glucan since Maillard and other by-products are minimized.

To prevent gellation of the cereal β-glucan at each of the steps of the purification method of the present invention, it is preferred that the addition of salts be minimized throughout the process. For example, it is preferred that reverse osmosis (RO) purified or deionized (DI) water be used, as well as an amylase not requiring a calcium cofactor, such as Termamyl® LC (Novozymes A/S).

Without wishing to be bound by theory, one way in which gellation of solutions of cereal β-glucan can take place is by cross-linking of the molecules of cereal β-glucan, which is initiated by coordination of the cereal β-glucan molecules to

ions, such as calcium. By using low amounts of salt throughout the process, cross-linking of cereal β-glucan molecules in the intermediate solutions formed in the method of the present invention, can, therefore, be minimized. In addition, by limiting the amount of salt introduced throughout the method of the present invention, the cereal β-glucan can be isolated essentially free of salts in the final step of the method.

The cereal β-glucan composition prepared by the purification method of the present invention generally has a purity of at least about 75%, and contains less than10% ash impurities, less than 10% protein impurities, and less than 5% lipid impurities. More particularly, the cereal β-glucan composition of the present invention has a purity of at least about 92%, and contains less than 3.5% ash impurities, less than 3.5% protein impurities, and less than 1% lipid impurities. The yield of cereal β-glucan prepared according to the purification method of the present invention is generally from about 70 to about 72%.

Homogeneous solutions of the precipitated cereal β-glucan can be prepared by suspending the cereal β-glucan in reverse osmosis treated or deionized water at a temperature of about 30°C to about 45°C for a period of about 20 to about 30 minutes, or until most of the cereal β-glucan has been solubilized. The solution may then be pasteurized and a preservative added.

Aqueous solutions containing 1% cereal β-glucan, isolated according to the method of the present invention, generally have the following characteristics:

- a viscosity of about 200 to about 1500 cP, more particularly about 1000 to about 1500 cP.
- a clarity value of about 5 to about 100 NTU (Nominal Turbidity Units), more particularly about 5 to about 40 NTU.
- an ash concentration of about 0.02% to about 0.2%, more particularly about 0.02% to about 0.07%.
- a protein concentration of about 0.02% to about 0.2%, more particularly about 0.02% to about 0.07%.

- a lipid concentration of about 0.005% to about 0.1%, more particularly about 0.005% to about 0.02%.

Stabilized solutions of cereal β-glucan isolated according to the method of the present invention can be prepared in the manner described in U.S. Patent No. 6,284,886. The preservatives used in the method described in U.S. Patent No. 6,284,886 should be one that is approved for human consumption and pharmaceutical use, such as, but not limited to potassium sorbate, sorbic acid, benzalkonium chloride, and parabens.

The cereal β-glucan isolated according to the method of the present invention is of particular use in wound healing, and in reducing wrinkles, where transfer of cereal β-glucan across intact skin, can lead to the rebuilding of collagen through the stimulation of fibroblast growth.

The pharmaceutical composition of the present invention can be used in the form of a spray, a liquid, which may in the form of drops, or a gel. In an example, the botanical extract, and the pharmaceutically active agent comprises compounds that are readily absorbed through the mucosa of the oral cavity, the mucosa of the nasal cavity, or through gum tissue.

It is preferred that the pharmaceutical compositions of the present invention containing an anesthetic be applied to a specific, localized region of the gums or a surface of the oral cavity of a subject. It is also preferred that the compositions of the present invention, which contain a vasodilating agent, such as nitroglycerin, be applied underneath the tongue of a subject. The pharmaceutical compositions of the present invention, which comprise an antihistamine, a decongestant, a corticosteroid, or a non-steroidal anti-inflammatory drug can be applied to the back of the oral cavity, or to the nasal cavity of a subject to allow medication released from the composition to be inhaled by the subject. Pharmaceutical compositions according to the present invention, which comprise a consumable botanical extract, may be used as a mouthrinse and expectorated after being used, or, alternatively, may be swallowed.

The pharmaceutical compositions of the present invention may contain a pharmaceutically acceptable diluent or carrier, which is chosen based on the intended route of administration and standard pharmaceutical practice.

The pharmaceutical compositions of the present invention may also be administered orally in the form of tablets or capsules containing excipients, such as starch or lactose, or in the form of elixirs or suspensions containing flavoring or coloring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of an isotonic sterile aqueous solution.

The pharmaceutical compositions of the present invention may also be administered topically when treating inflammatory conditions of the skin in the form of a cream, a jelly, a gel, a paste, or an ointment. For example, pharmaceutical compositions of the present invention, which contain, a corticosteroid, a non-steroidal anti-inflammatory drug, or a botanical extract may be used as a topical composition, in the form of a cream.

Example 2 demonstrates that β (1-3) β (1-4) glucan prepared according to the method of the present invention, and applied in the form of a topical composition to the surface of a section of skin, can significantly cross into the horny layer, the epidermis, the dermis and the subcutis layers of the skin. These results suggest that a pharmaceutically active agent or a botanical extract encapsulated by the β (1-3) β (1-4) glucan isolated according to the method of the present invention could also be effectively transferred down to the dermis and subcutis layers of the skin of a subject.

The cereal β-glucan content can be determined using a number of methods, known to those skilled in the art (McCleary AOAC method). For example, cereal β-glucan content can be assessed colorimetrically and/or by standard analytical techniques such as size exclusion chromatography and HPLC (see Wood *et al. Cereal Chem.* (1977) **54**:524; Wood *et al. Cereal Chem.* (1991) **68**:31-39; and Wood *et al. Cereal Chem.* (1991) **68**:530-536). β-glucans can also be analyzed enzymatically

using commercially available kits, such as Megazyme (Ireland) employing the techniques of McCleary and Glennie-Holmes *J. Inst. Brew.* (1985) **91**:285.

Viscosities can be measured with a rotational, shear-type viscometer such as the Brookfield Syncro-Lectric or the Haake Rotovisco. Methods of using the instrument are known to those skilled in the art. Routinely, measurements are made at four speeds of disc rotation at a constant temperature of 25°C.

The following examples are provided to exemplify the present invention. Variations and alterations will be readily apparent to those skilled in the art.

Example 1: Method for purifying cereal β-glucan derived from oat bran

Oat bran (The Quaker Oats Company) was slurried with alkaline reverse osmosis (RO) water at a pH of about 9.5 to a final solids concentration of 4-10%. The temperature was maintained at 45°C ± 5°C. The cereal β-glucan was extracted from the oat bran over a period of 30 minutes. After this time, the solids were removed by centrifugation with a decanter centrifuge. The centrate was cooled to room temperature, and the cationic flocculant SURFLOC® 34030 (Jes-Chem Ltd.) was added at a 0.2% concentration. Following an incubation period of 20 minutes, coagulated particulate material was removed by centrifugation using a disk-stack centrifuge. The pH of the centrate was adjusted to approximately neutral, heated to >72°C to gelatinize starch, and treated with the heat-stable amylase Termamyl® LC (Novozymes A/S). When the solution no longer produced a positive iodine test, the pH was reduced to about 4.0 to inactivate the enzyme, and the mixture was heated to 85°C for 30 minutes to denature the protein present. The solution was cooled to 4°C for one hour, and then heated to a temperature of about 72°C. An equivalent weight of CELITE® C300 (World Minerals) was added to the solution, and the mixture was then filtered using a filter-press containing 25 µm filter-papers and pre-coated to a depth of about 4 mm with CELITE® C65 (World Minerals). The filter press was preheated to a temperature of about 65°C, and the pH of the feedstream for the filter press was adjusted to 4.5 before the β-glucan solution was filtered. After the β-glucan solution was passed through the filter, the press was flushed with reverse osmosis

water resulting in a clear, pale yellow coloured β-glucan solution. The β-glucan solution was cooled to 5°C and 95% ethanol at a temperature of -20°C was added to a final volume of about 15% (w/w) with stirring. A suspension of β-glucan was formed that was immediately separated from the solution by centrifugation with a disk-stack centrifuge. The isolated solid β-glucan was added to RO water at 45°C, allowed to disperse and then heated to between 60-70°C to produce a clear colorless solution containing about 1% β-glucan. The separated β-glucan was colourless, had a purity of greater than 75%, a viscosity >500 cP, and an exception clarity <50 NTU, as measured using a turbidity meter.

Example 2. Quantification of the Distribution of Purified β-Glucan Applied as an Aqueous Composition to Abdominal Skin Sections

Human abdominal skin was received under informed consent from five healthy donors having undergone plastic surgery. The skin from each patient was liberated from subcutaneous fat, and cut into three sections. The skin sections were frozen in liquid nitrogen and sterilized overnight with a dose of 25 kGy of gamma-radiation. The irradiated samples were each mounted in a 20 mL volume FRANZ-CELL®-like perfusion chamber (PHACOCELL®, PhaCos GmbH, D-82131-Gauting, Germany; see Artmann, C. W. In vitro percutaneous absorption into human skin, *Fundam. Appl. Toxicol.*, 28, 1-5 (1996)) containing an acceptor medium. Using a microdose applicator, the irradiated samples of skin were coated with a 5 mg/cm^2 dosage of Composition 1455, Composition 1450 or a control composition. The Compositions 1455 and 1450 were aqueous compositions containing 5% and 50%, respectively, of the β (1-3) β (1-4) glucan prepared according to the isolation method of the present invention (see Example 1). The control composition was an aqueous composition that did not contain any β (1-3) β (1-4) glucan. The chamber was kept free of air bubbles while filling in order to ensure complete and even rinsing of the skin tissue. Pressure compensation, inside and outside of the chamber and a constant humidity of air was provided by ventilation. The skin temperature was monitored with temperature sensors, and the moisture content of the skin sections was monitored with a corneometer. The medium was regulated at 36°C and circulated continuously. Skin humidity was kept at about 65 corneometer units, and the skin surface temperature

was kept at 32°C via a ventilation channel. The above conditions were maintained by regulation of the temperature of the medium by using a heating plate at the base of the chamber, and air tubes, and by adjusting the flow of air in the chamber. The skin sections were supplied by the uniformly circulating nutrient medium, which rinsed their lower surfaces. The area of application for all samples was fixed at 10 cm^2. The skin samples were incubated for eight hours under non-occlusive (open) conditions.

At the end of the incubation period, swab samples of the skin sections were taken with both dry cotton gauze swabs and cotton gauze swabs moistened with 0.2 mL of 70% methanol/H_2O. The skin sections were removed from the Phacocell® chamber and immediately frozen in liquid nitrogen. The skin sections were then cut into 15 µm slices from the horny layer to the deeper dermis. The skin sections were allowed to air dry on clean glass slides and not fixed with any fluid. The slices were then stained with BACTIDROP™ Calcofluor White for 30 seconds and then washed of excess stain with deionized water. The staining and washing steps were repeated twice. The stained sample was covered with a clean glass cover slip and examined by fluorescence with a LEIKA® fluorescent microscope having an exciter filter ranging between 400-500 nm with a peak of 440 nm, a barrier filter of 500-520 nm, and a xenon arc (burner) lamp. BACTIDROP™ Calcofluor White is a non-specific fluorochrome that binds to cellulose, and upon excitation with long wavelength ultraviolet light delineates the cell walls of cellulose-containing organisms. The deposition of the β-glucan molecules was monitored and quantified using bright fluorescence, focus inverted to white spots (3 – 5 μm) seen upon the cell walls of the samples and in the intercellular interstices.

The mean percent depositions as determined by the above fluorescence staining method are shown in Table 3. Significant fluorescent staining values (>5%) were observed in the horny layer and in the epidermis of the skin samples treated with Composition 1455 and Composition 1450. Relatively lower values were observed in the dermis and subcutis layers of the skin samples treated with Composition 1450 and Composition 1455. Fluorescence staining values of <1% were observed with the skin sections that were treated with the control composition.

Table 3. Mean Percent Deposition of β (1-3) β (1-4) Glucan in Different Layers of Abdominal Skin

	Mean Percent Deposition					
	COMPOSITION 1455		COMPOSITION 1450		Control	
	Percent	Standard Deviation	Percent	Standard Deviation	Percent	Standard Deviation
Medium	-	-	-	-	-	-
Swab	-	-	-	-	-	-
Horny layer	8.7	1.2	12.8	1.9	0.6	0.2
Epidermis	5.9	1.3	11.6	2.0	0.8	0.2
Dermis	2.4	0.5	4.1	1.1	0.6	0.1
subcutis	1.4	0.5	1.5	0.4	0.9	0.1

The documentation of the findings by photographs (not shown) also demonstrated a significant uptake of the β-glucan into the epidermis layer of the skin samples.

The measurement of fluorescence was performed in accordance with quality control procedures and documentations. Control numbers of the BACTIDROP™ Calcofluor White were tested using recognized quality control organisms and were found to be acceptable.(Microbiology M. Pettenkofer Institute, München). Statistical evaluation was carried out by the statistics software package SAS/STATISTICA®. Both the hardware and the software used were validated.

Example 3. Preparation of a mouthwash or spray containing an avenanthramide-containing extract.

1 g of an oat extract containing 100 pm avenanthramide (Ceapro Inc.) was added to a stirred 10 % (w/w) solution of oat β (1-3) β (1-4) glucan (Ceapro Inc.) producing a clear near-colourless solution.

Example 4. Preparation of a mouthwash or spray containing a nutraceutical extract

An extract of *Echinacea angustifolia* (1000 mg) in 45% ethanol was added to a stirred solution of oat beta glucan (Ceapro Inc.) to achieve a final concentration of

0.5 % w/w oat beta glucan. The mixture was evaporated under reduced vacuum to remove the alcohol, affording a clear light amber solution.

The present invention has been described with regard to preferred embodiments. However, it will be obvious to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as described in the following claims.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A pharmaceutical composition comprising:
an effective amount of a β (1-3) β (1-4) glucan, and
an effective amount of a botanical extract, or a pharmaceutically active agent.

2. The pharmaceutical composition according to claim 1, wherein the composition comprises the botanical extract, and wherein the botanical extract is an extract of Guarana, *Ginkgo biloba*, Kola nut, Goldenseal, Golo Kola, *Schizandra*, Elderberry, St. John's Wort, Valerian and *Ephedra*, black tea, white tea, java tea, garlic oil, fiber, green tea, lemon oil, mace, licorice, onion oil, orange oil, rosemary, milk thistle, *Echinacea*, Siberian ginseng or *Panax ginseng*, lemon balm, *Kava kava*, matte, bilberry, soy, grapefruit, seaweed, hawthorn, lime blossom, sage, clove, basil, curcumin, taurine, wild oat herb, oat grain, dandelion, gentian, aloe vera, hops, cinnamon, peppermint, grape, chamomile, fennel, marshmallow, ginger, slippery elm, cardamon, coriander, anise, thyme, rehmannia, eucalyptus, menthol, schisandra, withania, cowslip, lycium, or passion flower.

3. The pharmaceutical composition according to claim 2, wherein the botanical extract is an extract of oat grain.

4. The pharmaceutical composition of claim 3, wherein the botanical extract comprises avenanthramide.

5. The pharmaceutical composition according to claim 1, wherein the composition comprises the pharmaceutically active agent, and wherein the pharmaceutically active agent is selected from the group consisting of beta-sitosterol, caffeine, cafestol, D-limonene, kabweol, nomilin, oltipraz, sulphoraphane, tangeretin, folic acid, and menthol.

6. The pharmaceutical composition according to claim 1, wherein the composition comprises the pharmaceutically active agent, and wherein the pharmaceutically active agent is selected from the group consisting of an

antihistamine, a decongestant, a corticosteroid, a non-steroidal anti-inflammatory drug, a bronchodilator, a vasodilator, such as nitroglycerin, and a local anaesthetic.

7. The pharmaceutical composition of claim 6, wherein the vasodilator is nitroglycerin.

8. The pharmaceutical composition according to claim 1, wherein the β (1-3) β (1-4) glucan is derived from a cereal grain or a part of the cereal grain.

9. The pharmaceutical composition according to claim 8, wherein the cereal is selected from the group consisting of a cultivar of barley, a cultivar of oat, a cultivar of wheat, a cultivar of rye, a cultivar of sorghum, a cultivar of millet, a cultivar of corn, and a mixture thereof.

10. The pharmaceutical composition according to claim 1, wherein the β (1-3) β (1-4) glucan is a β (1-3) β (1-4) glucan composition having a purity of at least about 75%, and containing less than10% ash impurities, less than 10% protein impurities, and less than 5% lipid impurities.

11. The pharmaceutical composition according to claim 10, wherein the β (1-3) β (1-4) glucan composition has a purity of at least about 92%, and contains less than 3.5% ash impurities, less than 3.5 % protein impurities, and less than 1% lipid impurities.

12. The pharmaceutical composition according to claim 10, wherein the cereal β-glucan composition has a clarity value of from about 5 to about 100 NTU.

13. The pharmaceutical composition according to claim 1, wherein the β (1-3) β (1-4) glucan is produced according to a method of isolating a β (1-3) β (1-4) glucan from a milled cereal grain or a milled part of the cereal grain, comprising:

(i) extracting the milled cereal grain or the milled part of the cereal grain with an alkaline solution to produce an extract containing at least about 0.4 weight percent β (1-3) β (1-4) glucan;

(ii) removing insoluble material, and removing particulate material having a particle size of greater than about 0.2 μm from said extract to produce a purified extract;

(iii) adding from about 10% to about 25% (w/w) of a C_1-C_4 alcohol to the purified extract to precipitate the β (1-3) β (1-4) glucan, and

(iv) isolating the β(1-3) β(1-4) glucan.

14. The pharmaceutical composition according to claim 13, wherein in said step of adding (step iii) in said method, about 10% to about 20% (w/w) of an alcohol selected from the group consisting of methanol, ethanol and isopropanol, is used to precipitate the β (1-3) β (1-4) glucan from said purified extract.

15. The pharmaceutical composition according to claim 14, wherein about 10% to about 20% (w/w) of ethanol is used to precipitate the β (1-3) β (1-4) glucan from said purified extract.

16. The pharmaceutical composition according to claim 13, wherein said step of removing particulate material in said method comprises:

one, or more than one step of adding a flocculant, a coagulant or both a flocculant and a coagulant to said extract to coagulate particulate material having a particle size of greater than about 0.2 μm, and removing coagulated material from said extract;

digesting starch material in said extract, and

filtering out particulate material having a particle size of greater than about 0.2 μm from said extract to produce a purified extract.

17. The pharmaceutical composition according to claim 16, wherein in said step of digesting in said method, said starch material is digested with an enzyme.

18. The pharmaceutical composition according to claim 17, wherein prior to digesting said starch material, said alkaline solution is neutralized.

19. The pharmaceutical composition according to claim 18, wherein following the digestion of said starch material in said method, said enzyme is inactivated.

20. The pharmaceutical composition according to claim 19, wherein said enzyme is inactivated by acidifying the neutralized solution.

21. The pharmaceutical composition according to claim 17, wherein said enzyme is an amylase.

22. The pharmaceutical composition according to claim 21, wherein said amylase does not require a calcium cofactor.

23. The pharmaceutical composition according to claim 13, wherein the cereal is selected from the group consisting of a cultivar of barley, a cultivar of oat, a cultivar of wheat, a cultivar of rye, a cultivar of sorghum, a cultivar of millet, a cultivar of corn, and a mixture thereof.

24. The pharmaceutical composition according to claim 13, wherein the pH of the alkaline solution used in said method is from about 9 to about 10.

25. The pharmaceutical composition according to claim 13, wherein said step of extracting (step i) in said method is carried out over a period of from about 15 to about 45 minutes.

26. The pharmaceutical composition according to claim 13, wherein said step of adding (step iii) in said method is conducted at a temperature of from about 1°C to about 10°C.

27. The pharmaceutical composition according to claim 13, wherein said method further comprises one, or more than one step of dissolving the isolated β (1-3) β (1-4) glucan in an aqueous solution, precipitating the β (1-3) β (1-4) glucan by adding about 10% to about 25% (w/w) of the C_1-C_4 alcohol to the aqueous solution, and isolating the β (1-3) β (1-4) glucan.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000662

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/716 A61K35/78 A61P17/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/43719 A (WEISSMAN GLENN H) 6 June 2002 (2002-06-06) example 2	1,2,8,9
X	WO 00/67626 A (FIELDER DAVID ; CEAPRO INC (CA); REDMOND MARK J (CA)) 16 November 2000 (2000-11-16) example 9	1-4
X	US 5 980 918 A (KLEIN BARBARA K) 9 November 1999 (1999-11-09) the whole document	1,8,9
X	WO 01/74300 A (BRENNEN MEDICAL INC) 11 October 2001 (2001-10-11) page 3, lines 1-4 page 8, lines 17-22	1,8,9

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 September 2004	11/10/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Pacreu Largo, M

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000662

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ESTRADA A ET AL: "Effect of administration of oat beta-glucan on immune parameters of healthy and immunosuppressed beef steers." CANADIAN JOURNAL OF VETERINARY RESEARCH = REVUE CANADIENNE DE RECHERCHE VETERINAIRE. OCT 1999, vol. 63, no. 4, October 1999 (1999-10), pages 261-268, XP002297977 ISSN: 0830-9000 page 263	1,6,8,9
P,X	WO 03/054077 A (CEAPRO INC ; FIELDER DAVID A (CA); REDMOND MARK J (CA)) 3 July 2003 (2003-07-03) page 8, lines 29-32; claims 1,10-14	1,5-11
A	ESTRADA ALBERTO ET AL: "Immunomodulatory activities of oat beta-glucan in vitro and in vivo" MICROBIOLOGY AND IMMUNOLOGY, vol. 41, no. 12, 1997, pages 991-998, XP009036004 ISSN: 0385-5600 abstract	1-27
A	CHEUNG NAI-KONG V ET AL: "Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies." CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 51, no. 10, November 2002 (2002-11), pages 557-564, XP002297978 ISSN: 0340-7004 abstract	1-27
A	YUN C-H ET AL: "'beta!-Glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections" FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 21 FEB 2003 NETHERLANDS, vol. 35, no. 1, 21 February 2003 (2003-02-21), pages 67-75, XP002297979 ISSN: 0928-8244 abstract	1-27

-/—

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000662

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BRAATEN J T ET AL: "OAT BETA-GLUCAN REDUCES BLOOD CHOLESTEROL CONCENTRATION IN HYPERCHOLESTEROLEMIC SUBJECTS" EUROPEAN JOURNAL OF CLINICAL NUTRITION, XX, XX, vol. 48, July 1994 (1994-07), pages 465-474, XP001027909 abstract	1-27
A	US 5 518 710 A (BHATTY RATTAN S) 21 May 1996 (1996-05-21) the whole document	1-27

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/CA2004/000662

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0243719 A	06-06-2002	AU	1994502 A	11-06-2002
		WO	0243719 A2	06-06-2002
		US	2002102316 A1	01-08-2002
WO 0067626 A	16-11-2000	AU	767424 B2	13-11-2003
		AU	5393200 A	21-11-2000
		CA	2368218 A1	16-11-2000
		WO	0067626 A2	16-11-2000
		EP	1185241 A2	13-03-2002
		JP	2002544145 T	24-12-2002
US 5980918 A	09-11-1999	CA	2304815 A1	06-05-1999
		EP	1024784 A1	09-08-2000
		JP	2001520982 T	06-11-2001
		WO	9921531 A1	06-05-1999
		US	6168799 B1	02-01-2001
WO 0174300 A	11-10-2001	AU	5087501 A	15-10-2001
		EP	1267795 A1	02-01-2003
		WO	0174300 A1	11-10-2001
		US	2004005364 A1	08-01-2004
WO 03054077 A	03-07-2003	WO	03054077 A1	03-07-2003
		CA	2467378 A1	03-07-2003
		EP	1453909 A1	08-09-2004
US 5518710 A	21-05-1996	NONE		